http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 21 Jul 2026 01:01:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Lupin+Spins+Out+Two+Oncology+Programs+to+Kaveri+Therapeutics+to+Advance+its+Oncology+Strategy/26790919.html <div class="xn-content"> <p class="prntac">Aims to <span>Raise Capital</span> to Fund Global Clinical Studies for LNP7457 (PRMT5) &amp; LNP8701 (SOS1)</p><p><span class="legendSpanClass"><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location> and <location value="LU/us.fl.naples" idsrc="xmltag.org" >NAPLES, Fla.</location></span>, <span class="legendSpanClass"><chron>July 21, 2026</chron></span> /PRNewswire/ -- Global pharmaceutical leader <b><span value="Bombay:500257" idsrc="xmltag.org" >Lupin Limited</span> (Lupin) </b>(BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced the strategic spin-out of two oncology programs – <a target="_blank" href="https://www.lupin.com/media/press-releases/lupin-announces-presentation-of-phase-1-data-on-lnp7457-prmt5-inhibitor-at-the-american-society-of-clinical-oncology-annual-meeting-2025" target="_blank" rel="nofollow">LNP7457 (PRMT5)</a> and <a target="_blank" href="https://www.lupin.com/media/press-releases/lupin-shares-phase-1-data-on-lnp-8701-at-the-asco-annual-meeting-2026" target="_blank" rel="nofollow">LNP8701 (SOS1)</a>, through its wholly owned subsidiary, <span value="ACORN:1254228097" idsrc="xmltag.org" >Lupin Inc.</span>, into <b><span>Kaveri Therapeutics Inc.</span> (Kaveri)</b>, a <location value="LC/us" idsrc="xmltag.org" >U.S</location>.-based clinical-stage oncology company. Kaveri will advance these programs through http://www.streetinsider.com/Press+Releases/Lupin+Spins+Out+Two+Oncology+Programs+to+Kaveri+Therapeutics+to+Advance+its+Oncology+Strategy/26790919.html Tue, 21 Jul 2026 01:01:00 -0400 500257 500257 A.01721546 A.12542280 A.50208902 A.50216726 LUPIN.BO LUPIN.NS O.01520983 O.03319887 O.11393334 O.21612337 O.22980248 http://www.streetinsider.com/Press+Releases/Lupin+Spins+Out+Two+Oncology+Programs+to+Kaveri+Therapeutics+to+Advance+its+Oncology+Strategy/26790919.html <div class="xn-content"> <p class="prntac">Aims to <span>Raise Capital</span> to Fund Global Clinical Studies for LNP7457 (PRMT5) &amp; LNP8701 (SOS1)</p><p><span class="legendSpanClass"><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location> and <location value="LU/us.fl.naples" idsrc="xmltag.org" >NAPLES, Fla.</location></span>, <span class="legendSpanClass"><chron>July 21, 2026</chron></span> /PRNewswire/ -- Global pharmaceutical leader <b><span value="Bombay:500257" idsrc="xmltag.org" >Lupin Limited</span> (Lupin) </b>(BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced the strategic spin-out of two oncology programs – <a target="_blank" href="https://www.lupin.com/media/press-releases/lupin-announces-presentation-of-phase-1-data-on-lnp7457-prmt5-inhibitor-at-the-american-society-of-clinical-oncology-annual-meeting-2025" target="_blank" rel="nofollow">LNP7457 (PRMT5)</a> and <a target="_blank" href="https://www.lupin.com/media/press-releases/lupin-shares-phase-1-data-on-lnp-8701-at-the-asco-annual-meeting-2026" target="_blank" rel="nofollow">LNP8701 (SOS1)</a>, through its wholly owned subsidiary, <span value="ACORN:1254228097" idsrc="xmltag.org" >Lupin Inc.</span>, into <b><span>Kaveri Therapeutics Inc.</span> (Kaveri)</b>, a <location value="LC/us" idsrc="xmltag.org" >U.S</location>.-based clinical-stage oncology company. Kaveri will advance these programs through http://www.streetinsider.com/Press+Releases/Lupin+Spins+Out+Two+Oncology+Programs+to+Kaveri+Therapeutics+to+Advance+its+Oncology+Strategy/26790919.html Tue, 21 Jul 2026 01:01:00 -0400 500257 500257 A.01721546 A.12542280 A.50208902 A.50216726 LUPIN.BO LUPIN.NS O.01520983 O.03319887 O.11393334 O.21612337 O.22980248 http://www.streetinsider.com/Press+Releases/Lupin+Spins+Out+Two+Oncology+Programs+to+Kaveri+Therapeutics+to+Advance+its+Oncology+Strategy/26790919.html <div class="xn-content"> <p class="prntac">Aims to <span>Raise Capital</span> to Fund Global Clinical Studies for LNP7457 (PRMT5) &amp; LNP8701 (SOS1)</p><p><span class="legendSpanClass"><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location> and <location value="LU/us.fl.naples" idsrc="xmltag.org" >NAPLES, Fla.</location></span>, <span class="legendSpanClass"><chron>July 21, 2026</chron></span> /PRNewswire/ -- Global pharmaceutical leader <b><span value="Bombay:500257" idsrc="xmltag.org" >Lupin Limited</span> (Lupin) </b>(BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced the strategic spin-out of two oncology programs – <a target="_blank" href="https://www.lupin.com/media/press-releases/lupin-announces-presentation-of-phase-1-data-on-lnp7457-prmt5-inhibitor-at-the-american-society-of-clinical-oncology-annual-meeting-2025" target="_blank" rel="nofollow">LNP7457 (PRMT5)</a> and <a target="_blank" href="https://www.lupin.com/media/press-releases/lupin-shares-phase-1-data-on-lnp-8701-at-the-asco-annual-meeting-2026" target="_blank" rel="nofollow">LNP8701 (SOS1)</a>, through its wholly owned subsidiary, <span value="ACORN:1254228097" idsrc="xmltag.org" >Lupin Inc.</span>, into <b><span>Kaveri Therapeutics Inc.</span> (Kaveri)</b>, a <location value="LC/us" idsrc="xmltag.org" >U.S</location>.-based clinical-stage oncology company. Kaveri will advance these programs through http://www.streetinsider.com/Press+Releases/Lupin+Spins+Out+Two+Oncology+Programs+to+Kaveri+Therapeutics+to+Advance+its+Oncology+Strategy/26790919.html Tue, 21 Jul 2026 01:01:00 -0400 500257 500257 A.01721546 A.12542280 A.50208902 A.50216726 LUPIN.BO LUPIN.NS O.01520983 O.03319887 O.11393334 O.21612337 O.22980248 http://www.streetinsider.com/Press+Releases/Lupin+Spins+Out+Two+Oncology+Programs+to+Kaveri+Therapeutics+to+Advance+its+Oncology+Strategy/26790919.html <div class="xn-content"> <p class="prntac">Aims to <span>Raise Capital</span> to Fund Global Clinical Studies for LNP7457 (PRMT5) &amp; LNP8701 (SOS1)</p><p><span class="legendSpanClass"><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location> and <location value="LU/us.fl.naples" idsrc="xmltag.org" >NAPLES, Fla.</location></span>, <span class="legendSpanClass"><chron>July 21, 2026</chron></span> /PRNewswire/ -- Global pharmaceutical leader <b><span value="Bombay:500257" idsrc="xmltag.org" >Lupin Limited</span> (Lupin) </b>(BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced the strategic spin-out of two oncology programs – <a target="_blank" href="https://www.lupin.com/media/press-releases/lupin-announces-presentation-of-phase-1-data-on-lnp7457-prmt5-inhibitor-at-the-american-society-of-clinical-oncology-annual-meeting-2025" target="_blank" rel="nofollow">LNP7457 (PRMT5)</a> and <a target="_blank" href="https://www.lupin.com/media/press-releases/lupin-shares-phase-1-data-on-lnp-8701-at-the-asco-annual-meeting-2026" target="_blank" rel="nofollow">LNP8701 (SOS1)</a>, through its wholly owned subsidiary, <span value="ACORN:1254228097" idsrc="xmltag.org" >Lupin Inc.</span>, into <b><span>Kaveri Therapeutics Inc.</span> (Kaveri)</b>, a <location value="LC/us" idsrc="xmltag.org" >U.S</location>.-based clinical-stage oncology company. Kaveri will advance these programs through http://www.streetinsider.com/Press+Releases/Lupin+Spins+Out+Two+Oncology+Programs+to+Kaveri+Therapeutics+to+Advance+its+Oncology+Strategy/26790919.html Tue, 21 Jul 2026 01:01:00 -0400 500257 500257 A.01721546 A.12542280 A.50208902 A.50216726 LUPIN.BO LUPIN.NS O.01520983 O.03319887 O.11393334 O.21612337 O.22980248 http://www.streetinsider.com/Press+Releases/Lupin+Spins+Out+Two+Oncology+Programs+to+Kaveri+Therapeutics+to+Advance+its+Oncology+Strategy/26790919.html <div class="xn-content"> <p class="prntac">Aims to <span>Raise Capital</span> to Fund Global Clinical Studies for LNP7457 (PRMT5) &amp; LNP8701 (SOS1)</p><p><span class="legendSpanClass"><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location> and <location value="LU/us.fl.naples" idsrc="xmltag.org" >NAPLES, Fla.</location></span>, <span class="legendSpanClass"><chron>July 21, 2026</chron></span> /PRNewswire/ -- Global pharmaceutical leader <b><span value="Bombay:500257" idsrc="xmltag.org" >Lupin Limited</span> (Lupin) </b>(BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced the strategic spin-out of two oncology programs – <a target="_blank" href="https://www.lupin.com/media/press-releases/lupin-announces-presentation-of-phase-1-data-on-lnp7457-prmt5-inhibitor-at-the-american-society-of-clinical-oncology-annual-meeting-2025" target="_blank" rel="nofollow">LNP7457 (PRMT5)</a> and <a target="_blank" href="https://www.lupin.com/media/press-releases/lupin-shares-phase-1-data-on-lnp-8701-at-the-asco-annual-meeting-2026" target="_blank" rel="nofollow">LNP8701 (SOS1)</a>, through its wholly owned subsidiary, <span value="ACORN:1254228097" idsrc="xmltag.org" >Lupin Inc.</span>, into <b><span>Kaveri Therapeutics Inc.</span> (Kaveri)</b>, a <location value="LC/us" idsrc="xmltag.org" >U.S</location>.-based clinical-stage oncology company. Kaveri will advance these programs through http://www.streetinsider.com/Press+Releases/Lupin+Spins+Out+Two+Oncology+Programs+to+Kaveri+Therapeutics+to+Advance+its+Oncology+Strategy/26790919.html Tue, 21 Jul 2026 01:01:00 -0400 500257 500257 A.01721546 A.12542280 A.50208902 A.50216726 LUPIN.BO LUPIN.NS O.01520983 O.03319887 O.11393334 O.21612337 O.22980248 http://www.streetinsider.com/Press+Releases/Lupin+Spins+Out+Two+Oncology+Programs+to+Kaveri+Therapeutics+to+Advance+its+Oncology+Strategy/26790919.html <div class="xn-content"> <p class="prntac">Aims to <span>Raise Capital</span> to Fund Global Clinical Studies for LNP7457 (PRMT5) &amp; LNP8701 (SOS1)</p><p><span class="legendSpanClass"><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location> and <location value="LU/us.fl.naples" idsrc="xmltag.org" >NAPLES, Fla.</location></span>, <span class="legendSpanClass"><chron>July 21, 2026</chron></span> /PRNewswire/ -- Global pharmaceutical leader <b><span value="Bombay:500257" idsrc="xmltag.org" >Lupin Limited</span> (Lupin) </b>(BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced the strategic spin-out of two oncology programs – <a target="_blank" href="https://www.lupin.com/media/press-releases/lupin-announces-presentation-of-phase-1-data-on-lnp7457-prmt5-inhibitor-at-the-american-society-of-clinical-oncology-annual-meeting-2025" target="_blank" rel="nofollow">LNP7457 (PRMT5)</a> and <a target="_blank" href="https://www.lupin.com/media/press-releases/lupin-shares-phase-1-data-on-lnp-8701-at-the-asco-annual-meeting-2026" target="_blank" rel="nofollow">LNP8701 (SOS1)</a>, through its wholly owned subsidiary, <span value="ACORN:1254228097" idsrc="xmltag.org" >Lupin Inc.</span>, into <b><span>Kaveri Therapeutics Inc.</span> (Kaveri)</b>, a <location value="LC/us" idsrc="xmltag.org" >U.S</location>.-based clinical-stage oncology company. Kaveri will advance these programs through http://www.streetinsider.com/Press+Releases/Lupin+Spins+Out+Two+Oncology+Programs+to+Kaveri+Therapeutics+to+Advance+its+Oncology+Strategy/26790919.html Tue, 21 Jul 2026 01:01:00 -0400 500257 500257 A.01721546 A.12542280 A.50208902 A.50216726 LUPIN.BO LUPIN.NS O.01520983 O.03319887 O.11393334 O.21612337 O.22980248 http://www.streetinsider.com/Press+Releases/Lupin+Spins+Out+Two+Oncology+Programs+to+Kaveri+Therapeutics+to+Advance+its+Oncology+Strategy/26790919.html <div class="xn-content"> <p class="prntac">Aims to <span>Raise Capital</span> to Fund Global Clinical Studies for LNP7457 (PRMT5) &amp; LNP8701 (SOS1)</p><p><span class="legendSpanClass"><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location> and <location value="LU/us.fl.naples" idsrc="xmltag.org" >NAPLES, Fla.</location></span>, <span class="legendSpanClass"><chron>July 21, 2026</chron></span> /PRNewswire/ -- Global pharmaceutical leader <b><span value="Bombay:500257" idsrc="xmltag.org" >Lupin Limited</span> (Lupin) </b>(BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced the strategic spin-out of two oncology programs – <a target="_blank" href="https://www.lupin.com/media/press-releases/lupin-announces-presentation-of-phase-1-data-on-lnp7457-prmt5-inhibitor-at-the-american-society-of-clinical-oncology-annual-meeting-2025" target="_blank" rel="nofollow">LNP7457 (PRMT5)</a> and <a target="_blank" href="https://www.lupin.com/media/press-releases/lupin-shares-phase-1-data-on-lnp-8701-at-the-asco-annual-meeting-2026" target="_blank" rel="nofollow">LNP8701 (SOS1)</a>, through its wholly owned subsidiary, <span value="ACORN:1254228097" idsrc="xmltag.org" >Lupin Inc.</span>, into <b><span>Kaveri Therapeutics Inc.</span> (Kaveri)</b>, a <location value="LC/us" idsrc="xmltag.org" >U.S</location>.-based clinical-stage oncology company. Kaveri will advance these programs through http://www.streetinsider.com/Press+Releases/Lupin+Spins+Out+Two+Oncology+Programs+to+Kaveri+Therapeutics+to+Advance+its+Oncology+Strategy/26790919.html Tue, 21 Jul 2026 01:01:00 -0400 500257 500257 A.01721546 A.12542280 A.50208902 A.50216726 LUPIN.BO LUPIN.NS O.01520983 O.03319887 O.11393334 O.21612337 O.22980248 http://www.streetinsider.com/Press+Releases/Lupin+Spins+Out+Two+Oncology+Programs+to+Kaveri+Therapeutics+to+Advance+its+Oncology+Strategy/26790919.html <div class="xn-content"> <p class="prntac">Aims to <span>Raise Capital</span> to Fund Global Clinical Studies for LNP7457 (PRMT5) &amp; LNP8701 (SOS1)</p><p><span class="legendSpanClass"><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location> and <location value="LU/us.fl.naples" idsrc="xmltag.org" >NAPLES, Fla.</location></span>, <span class="legendSpanClass"><chron>July 21, 2026</chron></span> /PRNewswire/ -- Global pharmaceutical leader <b><span value="Bombay:500257" idsrc="xmltag.org" >Lupin Limited</span> (Lupin) </b>(BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced the strategic spin-out of two oncology programs – <a target="_blank" href="https://www.lupin.com/media/press-releases/lupin-announces-presentation-of-phase-1-data-on-lnp7457-prmt5-inhibitor-at-the-american-society-of-clinical-oncology-annual-meeting-2025" target="_blank" rel="nofollow">LNP7457 (PRMT5)</a> and <a target="_blank" href="https://www.lupin.com/media/press-releases/lupin-shares-phase-1-data-on-lnp-8701-at-the-asco-annual-meeting-2026" target="_blank" rel="nofollow">LNP8701 (SOS1)</a>, through its wholly owned subsidiary, <span value="ACORN:1254228097" idsrc="xmltag.org" >Lupin Inc.</span>, into <b><span>Kaveri Therapeutics Inc.</span> (Kaveri)</b>, a <location value="LC/us" idsrc="xmltag.org" >U.S</location>.-based clinical-stage oncology company. Kaveri will advance these programs through http://www.streetinsider.com/Press+Releases/Lupin+Spins+Out+Two+Oncology+Programs+to+Kaveri+Therapeutics+to+Advance+its+Oncology+Strategy/26790919.html Tue, 21 Jul 2026 01:01:00 -0400 500257 500257 A.01721546 A.12542280 A.50208902 A.50216726 LUPIN.BO LUPIN.NS O.01520983 O.03319887 O.11393334 O.21612337 O.22980248 http://www.streetinsider.com/Press+Releases/Lupin+Spins+Out+Two+Oncology+Programs+to+Kaveri+Therapeutics+to+Advance+its+Oncology+Strategy/26790919.html <div class="xn-content"> <p class="prntac">Aims to <span>Raise Capital</span> to Fund Global Clinical Studies for LNP7457 (PRMT5) &amp; LNP8701 (SOS1)</p><p><span class="legendSpanClass"><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location> and <location value="LU/us.fl.naples" idsrc="xmltag.org" >NAPLES, Fla.</location></span>, <span class="legendSpanClass"><chron>July 21, 2026</chron></span> /PRNewswire/ -- Global pharmaceutical leader <b><span value="Bombay:500257" idsrc="xmltag.org" >Lupin Limited</span> (Lupin) </b>(BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced the strategic spin-out of two oncology programs – <a target="_blank" href="https://www.lupin.com/media/press-releases/lupin-announces-presentation-of-phase-1-data-on-lnp7457-prmt5-inhibitor-at-the-american-society-of-clinical-oncology-annual-meeting-2025" target="_blank" rel="nofollow">LNP7457 (PRMT5)</a> and <a target="_blank" href="https://www.lupin.com/media/press-releases/lupin-shares-phase-1-data-on-lnp-8701-at-the-asco-annual-meeting-2026" target="_blank" rel="nofollow">LNP8701 (SOS1)</a>, through its wholly owned subsidiary, <span value="ACORN:1254228097" idsrc="xmltag.org" >Lupin Inc.</span>, into <b><span>Kaveri Therapeutics Inc.</span> (Kaveri)</b>, a <location value="LC/us" idsrc="xmltag.org" >U.S</location>.-based clinical-stage oncology company. Kaveri will advance these programs through http://www.streetinsider.com/Press+Releases/Lupin+Spins+Out+Two+Oncology+Programs+to+Kaveri+Therapeutics+to+Advance+its+Oncology+Strategy/26790919.html Tue, 21 Jul 2026 01:01:00 -0400 500257 500257 A.01721546 A.12542280 A.50208902 A.50216726 LUPIN.BO LUPIN.NS O.01520983 O.03319887 O.11393334 O.21612337 O.22980248 http://www.streetinsider.com/Press+Releases/Lupin+Spins+Out+Two+Oncology+Programs+to+Kaveri+Therapeutics+to+Advance+its+Oncology+Strategy/26790919.html <div class="xn-content"> <p class="prntac">Aims to <span>Raise Capital</span> to Fund Global Clinical Studies for LNP7457 (PRMT5) &amp; LNP8701 (SOS1)</p><p><span class="legendSpanClass"><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location> and <location value="LU/us.fl.naples" idsrc="xmltag.org" >NAPLES, Fla.</location></span>, <span class="legendSpanClass"><chron>July 21, 2026</chron></span> /PRNewswire/ -- Global pharmaceutical leader <b><span value="Bombay:500257" idsrc="xmltag.org" >Lupin Limited</span> (Lupin) </b>(BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced the strategic spin-out of two oncology programs – <a target="_blank" href="https://www.lupin.com/media/press-releases/lupin-announces-presentation-of-phase-1-data-on-lnp7457-prmt5-inhibitor-at-the-american-society-of-clinical-oncology-annual-meeting-2025" target="_blank" rel="nofollow">LNP7457 (PRMT5)</a> and <a target="_blank" href="https://www.lupin.com/media/press-releases/lupin-shares-phase-1-data-on-lnp-8701-at-the-asco-annual-meeting-2026" target="_blank" rel="nofollow">LNP8701 (SOS1)</a>, through its wholly owned subsidiary, <span value="ACORN:1254228097" idsrc="xmltag.org" >Lupin Inc.</span>, into <b><span>Kaveri Therapeutics Inc.</span> (Kaveri)</b>, a <location value="LC/us" idsrc="xmltag.org" >U.S</location>.-based clinical-stage oncology company. Kaveri will advance these programs through http://www.streetinsider.com/Press+Releases/Lupin+Spins+Out+Two+Oncology+Programs+to+Kaveri+Therapeutics+to+Advance+its+Oncology+Strategy/26790919.html Tue, 21 Jul 2026 01:01:00 -0400 500257 500257 A.01721546 A.12542280 A.50208902 A.50216726 LUPIN.BO LUPIN.NS O.01520983 O.03319887 O.11393334 O.21612337 O.22980248 http://www.streetinsider.com/Press+Releases/Lupin+Spins+Out+Two+Oncology+Programs+to+Kaveri+Therapeutics+to+Advance+its+Oncology+Strategy/26790919.html <div class="xn-content"> <p class="prntac">Aims to <span>Raise Capital</span> to Fund Global Clinical Studies for LNP7457 (PRMT5) &amp; LNP8701 (SOS1)</p><p><span class="legendSpanClass"><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location> and <location value="LU/us.fl.naples" idsrc="xmltag.org" >NAPLES, Fla.</location></span>, <span class="legendSpanClass"><chron>July 21, 2026</chron></span> /PRNewswire/ -- Global pharmaceutical leader <b><span value="Bombay:500257" idsrc="xmltag.org" >Lupin Limited</span> (Lupin) </b>(BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced the strategic spin-out of two oncology programs – <a target="_blank" href="https://www.lupin.com/media/press-releases/lupin-announces-presentation-of-phase-1-data-on-lnp7457-prmt5-inhibitor-at-the-american-society-of-clinical-oncology-annual-meeting-2025" target="_blank" rel="nofollow">LNP7457 (PRMT5)</a> and <a target="_blank" href="https://www.lupin.com/media/press-releases/lupin-shares-phase-1-data-on-lnp-8701-at-the-asco-annual-meeting-2026" target="_blank" rel="nofollow">LNP8701 (SOS1)</a>, through its wholly owned subsidiary, <span value="ACORN:1254228097" idsrc="xmltag.org" >Lupin Inc.</span>, into <b><span>Kaveri Therapeutics Inc.</span> (Kaveri)</b>, a <location value="LC/us" idsrc="xmltag.org" >U.S</location>.-based clinical-stage oncology company. Kaveri will advance these programs through http://www.streetinsider.com/Press+Releases/Lupin+Spins+Out+Two+Oncology+Programs+to+Kaveri+Therapeutics+to+Advance+its+Oncology+Strategy/26790919.html Tue, 21 Jul 2026 01:01:00 -0400 500257 500257 A.01721546 A.12542280 A.50208902 A.50216726 LUPIN.BO LUPIN.NS O.01520983 O.03319887 O.11393334 O.21612337 O.22980248 http://www.streetinsider.com/Press+Releases/Lupin+Spins+Out+Two+Oncology+Programs+to+Kaveri+Therapeutics+to+Advance+its+Oncology+Strategy/26790919.html <div class="xn-content"> <p class="prntac">Aims to <span>Raise Capital</span> to Fund Global Clinical Studies for LNP7457 (PRMT5) &amp; LNP8701 (SOS1)</p><p><span class="legendSpanClass"><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location> and <location value="LU/us.fl.naples" idsrc="xmltag.org" >NAPLES, Fla.</location></span>, <span class="legendSpanClass"><chron>July 21, 2026</chron></span> /PRNewswire/ -- Global pharmaceutical leader <b><span value="Bombay:500257" idsrc="xmltag.org" >Lupin Limited</span> (Lupin) </b>(BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced the strategic spin-out of two oncology programs – <a target="_blank" href="https://www.lupin.com/media/press-releases/lupin-announces-presentation-of-phase-1-data-on-lnp7457-prmt5-inhibitor-at-the-american-society-of-clinical-oncology-annual-meeting-2025" target="_blank" rel="nofollow">LNP7457 (PRMT5)</a> and <a target="_blank" href="https://www.lupin.com/media/press-releases/lupin-shares-phase-1-data-on-lnp-8701-at-the-asco-annual-meeting-2026" target="_blank" rel="nofollow">LNP8701 (SOS1)</a>, through its wholly owned subsidiary, <span value="ACORN:1254228097" idsrc="xmltag.org" >Lupin Inc.</span>, into <b><span>Kaveri Therapeutics Inc.</span> (Kaveri)</b>, a <location value="LC/us" idsrc="xmltag.org" >U.S</location>.-based clinical-stage oncology company. Kaveri will advance these programs through http://www.streetinsider.com/Press+Releases/Lupin+Spins+Out+Two+Oncology+Programs+to+Kaveri+Therapeutics+to+Advance+its+Oncology+Strategy/26790919.html Tue, 21 Jul 2026 01:01:00 -0400 500257 500257 A.01721546 A.12542280 A.50208902 A.50216726 LUPIN.BO LUPIN.NS O.01520983 O.03319887 O.11393334 O.21612337 O.22980248 http://www.streetinsider.com/Press+Releases/Lupin+Spins+Out+Two+Oncology+Programs+to+Kaveri+Therapeutics+to+Advance+its+Oncology+Strategy/26790919.html <div class="xn-content"> <p class="prntac">Aims to <span>Raise Capital</span> to Fund Global Clinical Studies for LNP7457 (PRMT5) &amp; LNP8701 (SOS1)</p><p><span class="legendSpanClass"><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location> and <location value="LU/us.fl.naples" idsrc="xmltag.org" >NAPLES, Fla.</location></span>, <span class="legendSpanClass"><chron>July 21, 2026</chron></span> /PRNewswire/ -- Global pharmaceutical leader <b><span value="Bombay:500257" idsrc="xmltag.org" >Lupin Limited</span> (Lupin) </b>(BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced the strategic spin-out of two oncology programs – <a target="_blank" href="https://www.lupin.com/media/press-releases/lupin-announces-presentation-of-phase-1-data-on-lnp7457-prmt5-inhibitor-at-the-american-society-of-clinical-oncology-annual-meeting-2025" target="_blank" rel="nofollow">LNP7457 (PRMT5)</a> and <a target="_blank" href="https://www.lupin.com/media/press-releases/lupin-shares-phase-1-data-on-lnp-8701-at-the-asco-annual-meeting-2026" target="_blank" rel="nofollow">LNP8701 (SOS1)</a>, through its wholly owned subsidiary, <span value="ACORN:1254228097" idsrc="xmltag.org" >Lupin Inc.</span>, into <b><span>Kaveri Therapeutics Inc.</span> (Kaveri)</b>, a <location value="LC/us" idsrc="xmltag.org" >U.S</location>.-based clinical-stage oncology company. Kaveri will advance these programs through http://www.streetinsider.com/Press+Releases/Lupin+Spins+Out+Two+Oncology+Programs+to+Kaveri+Therapeutics+to+Advance+its+Oncology+Strategy/26790919.html Tue, 21 Jul 2026 01:01:00 -0400 500257 500257 A.01721546 A.12542280 A.50208902 A.50216726 LUPIN.BO LUPIN.NS O.01520983 O.03319887 O.11393334 O.21612337 O.22980248 http://www.streetinsider.com/PRNewswire/Lupin+Spins+Out+Two+Oncology+Programs+to+Kaveri+Therapeutics+to+Advance+its+Oncology+Strategy/26790919.html <div class="xn-content"> <p class="prntac">Aims to <span>Raise Capital</span> to Fund Global Clinical Studies for LNP7457 (PRMT5) &amp; LNP8701 (SOS1)</p><p><span class="legendSpanClass"><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location> and <location value="LU/us.fl.naples" idsrc="xmltag.org" >NAPLES, Fla.</location></span>, <span class="legendSpanClass"><chron>July 21, 2026</chron></span> /PRNewswire/ -- Global pharmaceutical leader <b><span value="Bombay:500257" idsrc="xmltag.org" >Lupin Limited</span> (Lupin) </b>(BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced the strategic spin-out of two oncology programs – <a target="_blank" href="https://www.lupin.com/media/press-releases/lupin-announces-presentation-of-phase-1-data-on-lnp7457-prmt5-inhibitor-at-the-american-society-of-clinical-oncology-annual-meeting-2025" target="_blank" rel="nofollow">LNP7457 (PRMT5)</a> and <a target="_blank" href="https://www.lupin.com/media/press-releases/lupin-shares-phase-1-data-on-lnp-8701-at-the-asco-annual-meeting-2026" target="_blank" rel="nofollow">LNP8701 (SOS1)</a>, through its wholly owned subsidiary, <span value="ACORN:1254228097" idsrc="xmltag.org" >Lupin Inc.</span>, into <b><span>Kaveri Therapeutics Inc.</span> (Kaveri)</b>, a <location value="LC/us" idsrc="xmltag.org" >U.S</location>.-based clinical-stage oncology company. Kaveri will advance these programs through http://www.streetinsider.com/PRNewswire/Lupin+Spins+Out+Two+Oncology+Programs+to+Kaveri+Therapeutics+to+Advance+its+Oncology+Strategy/26790919.html Tue, 21 Jul 2026 01:01:00 -0400 500257 500257 A.01721546 A.12542280 A.50208902 A.50216726 LUPIN.BO LUPIN.NS O.01520983 O.03319887 O.11393334 O.21612337 O.22980248 http://www.streetinsider.com/PRNewswire/Lupin+Spins+Out+Two+Oncology+Programs+to+Kaveri+Therapeutics+to+Advance+its+Oncology+Strategy/26790919.html <div class="xn-content"> <p class="prntac">Aims to <span>Raise Capital</span> to Fund Global Clinical Studies for LNP7457 (PRMT5) &amp; LNP8701 (SOS1)</p><p><span class="legendSpanClass"><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location> and <location value="LU/us.fl.naples" idsrc="xmltag.org" >NAPLES, Fla.</location></span>, <span class="legendSpanClass"><chron>July 21, 2026</chron></span> /PRNewswire/ -- Global pharmaceutical leader <b><span value="Bombay:500257" idsrc="xmltag.org" >Lupin Limited</span> (Lupin) </b>(BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced the strategic spin-out of two oncology programs – <a target="_blank" href="https://www.lupin.com/media/press-releases/lupin-announces-presentation-of-phase-1-data-on-lnp7457-prmt5-inhibitor-at-the-american-society-of-clinical-oncology-annual-meeting-2025" target="_blank" rel="nofollow">LNP7457 (PRMT5)</a> and <a target="_blank" href="https://www.lupin.com/media/press-releases/lupin-shares-phase-1-data-on-lnp-8701-at-the-asco-annual-meeting-2026" target="_blank" rel="nofollow">LNP8701 (SOS1)</a>, through its wholly owned subsidiary, <span value="ACORN:1254228097" idsrc="xmltag.org" >Lupin Inc.</span>, into <b><span>Kaveri Therapeutics Inc.</span> (Kaveri)</b>, a <location value="LC/us" idsrc="xmltag.org" >U.S</location>.-based clinical-stage oncology company. Kaveri will advance these programs through http://www.streetinsider.com/PRNewswire/Lupin+Spins+Out+Two+Oncology+Programs+to+Kaveri+Therapeutics+to+Advance+its+Oncology+Strategy/26790919.html Tue, 21 Jul 2026 01:01:00 -0400 500257 500257 A.01721546 A.12542280 A.50208902 A.50216726 LUPIN.BO LUPIN.NS O.01520983 O.03319887 O.11393334 O.21612337 O.22980248 http://www.streetinsider.com/PRNewswire/Lupin+Spins+Out+Two+Oncology+Programs+to+Kaveri+Therapeutics+to+Advance+its+Oncology+Strategy/26790919.html <div class="xn-content"> <p class="prntac">Aims to <span>Raise Capital</span> to Fund Global Clinical Studies for LNP7457 (PRMT5) &amp; LNP8701 (SOS1)</p><p><span class="legendSpanClass"><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location> and <location value="LU/us.fl.naples" idsrc="xmltag.org" >NAPLES, Fla.</location></span>, <span class="legendSpanClass"><chron>July 21, 2026</chron></span> /PRNewswire/ -- Global pharmaceutical leader <b><span value="Bombay:500257" idsrc="xmltag.org" >Lupin Limited</span> (Lupin) </b>(BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced the strategic spin-out of two oncology programs – <a target="_blank" href="https://www.lupin.com/media/press-releases/lupin-announces-presentation-of-phase-1-data-on-lnp7457-prmt5-inhibitor-at-the-american-society-of-clinical-oncology-annual-meeting-2025" target="_blank" rel="nofollow">LNP7457 (PRMT5)</a> and <a target="_blank" href="https://www.lupin.com/media/press-releases/lupin-shares-phase-1-data-on-lnp-8701-at-the-asco-annual-meeting-2026" target="_blank" rel="nofollow">LNP8701 (SOS1)</a>, through its wholly owned subsidiary, <span value="ACORN:1254228097" idsrc="xmltag.org" >Lupin Inc.</span>, into <b><span>Kaveri Therapeutics Inc.</span> (Kaveri)</b>, a <location value="LC/us" idsrc="xmltag.org" >U.S</location>.-based clinical-stage oncology company. Kaveri will advance these programs through http://www.streetinsider.com/PRNewswire/Lupin+Spins+Out+Two+Oncology+Programs+to+Kaveri+Therapeutics+to+Advance+its+Oncology+Strategy/26790919.html Tue, 21 Jul 2026 01:01:00 -0400 500257 500257 A.01721546 A.12542280 A.50208902 A.50216726 LUPIN.BO LUPIN.NS O.01520983 O.03319887 O.11393334 O.21612337 O.22980248 http://www.streetinsider.com/PRNewswire/Lupin+Spins+Out+Two+Oncology+Programs+to+Kaveri+Therapeutics+to+Advance+its+Oncology+Strategy/26790919.html <div class="xn-content"> <p class="prntac">Aims to <span>Raise Capital</span> to Fund Global Clinical Studies for LNP7457 (PRMT5) &amp; LNP8701 (SOS1)</p><p><span class="legendSpanClass"><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location> and <location value="LU/us.fl.naples" idsrc="xmltag.org" >NAPLES, Fla.</location></span>, <span class="legendSpanClass"><chron>July 21, 2026</chron></span> /PRNewswire/ -- Global pharmaceutical leader <b><span value="Bombay:500257" idsrc="xmltag.org" >Lupin Limited</span> (Lupin) </b>(BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced the strategic spin-out of two oncology programs – <a target="_blank" href="https://www.lupin.com/media/press-releases/lupin-announces-presentation-of-phase-1-data-on-lnp7457-prmt5-inhibitor-at-the-american-society-of-clinical-oncology-annual-meeting-2025" target="_blank" rel="nofollow">LNP7457 (PRMT5)</a> and <a target="_blank" href="https://www.lupin.com/media/press-releases/lupin-shares-phase-1-data-on-lnp-8701-at-the-asco-annual-meeting-2026" target="_blank" rel="nofollow">LNP8701 (SOS1)</a>, through its wholly owned subsidiary, <span value="ACORN:1254228097" idsrc="xmltag.org" >Lupin Inc.</span>, into <b><span>Kaveri Therapeutics Inc.</span> (Kaveri)</b>, a <location value="LC/us" idsrc="xmltag.org" >U.S</location>.-based clinical-stage oncology company. Kaveri will advance these programs through http://www.streetinsider.com/PRNewswire/Lupin+Spins+Out+Two+Oncology+Programs+to+Kaveri+Therapeutics+to+Advance+its+Oncology+Strategy/26790919.html Tue, 21 Jul 2026 01:01:00 -0400 500257 500257 A.01721546 A.12542280 A.50208902 A.50216726 LUPIN.BO LUPIN.NS O.01520983 O.03319887 O.11393334 O.21612337 O.22980248 http://www.streetinsider.com/PRNewswire/Lupin+Spins+Out+Two+Oncology+Programs+to+Kaveri+Therapeutics+to+Advance+its+Oncology+Strategy/26790919.html <div class="xn-content"> <p class="prntac">Aims to <span>Raise Capital</span> to Fund Global Clinical Studies for LNP7457 (PRMT5) &amp; LNP8701 (SOS1)</p><p><span class="legendSpanClass"><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location> and <location value="LU/us.fl.naples" idsrc="xmltag.org" >NAPLES, Fla.</location></span>, <span class="legendSpanClass"><chron>July 21, 2026</chron></span> /PRNewswire/ -- Global pharmaceutical leader <b><span value="Bombay:500257" idsrc="xmltag.org" >Lupin Limited</span> (Lupin) </b>(BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced the strategic spin-out of two oncology programs – <a target="_blank" href="https://www.lupin.com/media/press-releases/lupin-announces-presentation-of-phase-1-data-on-lnp7457-prmt5-inhibitor-at-the-american-society-of-clinical-oncology-annual-meeting-2025" target="_blank" rel="nofollow">LNP7457 (PRMT5)</a> and <a target="_blank" href="https://www.lupin.com/media/press-releases/lupin-shares-phase-1-data-on-lnp-8701-at-the-asco-annual-meeting-2026" target="_blank" rel="nofollow">LNP8701 (SOS1)</a>, through its wholly owned subsidiary, <span value="ACORN:1254228097" idsrc="xmltag.org" >Lupin Inc.</span>, into <b><span>Kaveri Therapeutics Inc.</span> (Kaveri)</b>, a <location value="LC/us" idsrc="xmltag.org" >U.S</location>.-based clinical-stage oncology company. Kaveri will advance these programs through http://www.streetinsider.com/PRNewswire/Lupin+Spins+Out+Two+Oncology+Programs+to+Kaveri+Therapeutics+to+Advance+its+Oncology+Strategy/26790919.html Tue, 21 Jul 2026 01:01:00 -0400 500257 500257 A.01721546 A.12542280 A.50208902 A.50216726 LUPIN.BO LUPIN.NS O.01520983 O.03319887 O.11393334 O.21612337 O.22980248 http://www.streetinsider.com/PRNewswire/Lupin+Spins+Out+Two+Oncology+Programs+to+Kaveri+Therapeutics+to+Advance+its+Oncology+Strategy/26790919.html <div class="xn-content"> <p class="prntac">Aims to <span>Raise Capital</span> to Fund Global Clinical Studies for LNP7457 (PRMT5) &amp; LNP8701 (SOS1)</p><p><span class="legendSpanClass"><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location> and <location value="LU/us.fl.naples" idsrc="xmltag.org" >NAPLES, Fla.</location></span>, <span class="legendSpanClass"><chron>July 21, 2026</chron></span> /PRNewswire/ -- Global pharmaceutical leader <b><span value="Bombay:500257" idsrc="xmltag.org" >Lupin Limited</span> (Lupin) </b>(BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced the strategic spin-out of two oncology programs – <a target="_blank" href="https://www.lupin.com/media/press-releases/lupin-announces-presentation-of-phase-1-data-on-lnp7457-prmt5-inhibitor-at-the-american-society-of-clinical-oncology-annual-meeting-2025" target="_blank" rel="nofollow">LNP7457 (PRMT5)</a> and <a target="_blank" href="https://www.lupin.com/media/press-releases/lupin-shares-phase-1-data-on-lnp-8701-at-the-asco-annual-meeting-2026" target="_blank" rel="nofollow">LNP8701 (SOS1)</a>, through its wholly owned subsidiary, <span value="ACORN:1254228097" idsrc="xmltag.org" >Lupin Inc.</span>, into <b><span>Kaveri Therapeutics Inc.</span> (Kaveri)</b>, a <location value="LC/us" idsrc="xmltag.org" >U.S</location>.-based clinical-stage oncology company. Kaveri will advance these programs through http://www.streetinsider.com/PRNewswire/Lupin+Spins+Out+Two+Oncology+Programs+to+Kaveri+Therapeutics+to+Advance+its+Oncology+Strategy/26790919.html Tue, 21 Jul 2026 01:01:00 -0400 500257 500257 A.01721546 A.12542280 A.50208902 A.50216726 LUPIN.BO LUPIN.NS O.01520983 O.03319887 O.11393334 O.21612337 O.22980248 http://www.streetinsider.com/PRNewswire/Lupin+Spins+Out+Two+Oncology+Programs+to+Kaveri+Therapeutics+to+Advance+its+Oncology+Strategy/26790919.html <div class="xn-content"> <p class="prntac">Aims to <span>Raise Capital</span> to Fund Global Clinical Studies for LNP7457 (PRMT5) &amp; LNP8701 (SOS1)</p><p><span class="legendSpanClass"><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location> and <location value="LU/us.fl.naples" idsrc="xmltag.org" >NAPLES, Fla.</location></span>, <span class="legendSpanClass"><chron>July 21, 2026</chron></span> /PRNewswire/ -- Global pharmaceutical leader <b><span value="Bombay:500257" idsrc="xmltag.org" >Lupin Limited</span> (Lupin) </b>(BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced the strategic spin-out of two oncology programs – <a target="_blank" href="https://www.lupin.com/media/press-releases/lupin-announces-presentation-of-phase-1-data-on-lnp7457-prmt5-inhibitor-at-the-american-society-of-clinical-oncology-annual-meeting-2025" target="_blank" rel="nofollow">LNP7457 (PRMT5)</a> and <a target="_blank" href="https://www.lupin.com/media/press-releases/lupin-shares-phase-1-data-on-lnp-8701-at-the-asco-annual-meeting-2026" target="_blank" rel="nofollow">LNP8701 (SOS1)</a>, through its wholly owned subsidiary, <span value="ACORN:1254228097" idsrc="xmltag.org" >Lupin Inc.</span>, into <b><span>Kaveri Therapeutics Inc.</span> (Kaveri)</b>, a <location value="LC/us" idsrc="xmltag.org" >U.S</location>.-based clinical-stage oncology company. Kaveri will advance these programs through http://www.streetinsider.com/PRNewswire/Lupin+Spins+Out+Two+Oncology+Programs+to+Kaveri+Therapeutics+to+Advance+its+Oncology+Strategy/26790919.html Tue, 21 Jul 2026 01:01:00 -0400 500257 500257 A.01721546 A.12542280 A.50208902 A.50216726 LUPIN.BO LUPIN.NS O.01520983 O.03319887 O.11393334 O.21612337 O.22980248 http://www.streetinsider.com/PRNewswire/Lupin+Spins+Out+Two+Oncology+Programs+to+Kaveri+Therapeutics+to+Advance+its+Oncology+Strategy/26790919.html <div class="xn-content"> <p class="prntac">Aims to <span>Raise Capital</span> to Fund Global Clinical Studies for LNP7457 (PRMT5) &amp; LNP8701 (SOS1)</p><p><span class="legendSpanClass"><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location> and <location value="LU/us.fl.naples" idsrc="xmltag.org" >NAPLES, Fla.</location></span>, <span class="legendSpanClass"><chron>July 21, 2026</chron></span> /PRNewswire/ -- Global pharmaceutical leader <b><span value="Bombay:500257" idsrc="xmltag.org" >Lupin Limited</span> (Lupin) </b>(BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced the strategic spin-out of two oncology programs – <a target="_blank" href="https://www.lupin.com/media/press-releases/lupin-announces-presentation-of-phase-1-data-on-lnp7457-prmt5-inhibitor-at-the-american-society-of-clinical-oncology-annual-meeting-2025" target="_blank" rel="nofollow">LNP7457 (PRMT5)</a> and <a target="_blank" href="https://www.lupin.com/media/press-releases/lupin-shares-phase-1-data-on-lnp-8701-at-the-asco-annual-meeting-2026" target="_blank" rel="nofollow">LNP8701 (SOS1)</a>, through its wholly owned subsidiary, <span value="ACORN:1254228097" idsrc="xmltag.org" >Lupin Inc.</span>, into <b><span>Kaveri Therapeutics Inc.</span> (Kaveri)</b>, a <location value="LC/us" idsrc="xmltag.org" >U.S</location>.-based clinical-stage oncology company. Kaveri will advance these programs through http://www.streetinsider.com/PRNewswire/Lupin+Spins+Out+Two+Oncology+Programs+to+Kaveri+Therapeutics+to+Advance+its+Oncology+Strategy/26790919.html Tue, 21 Jul 2026 01:01:00 -0400 500257 500257 A.01721546 A.12542280 A.50208902 A.50216726 LUPIN.BO LUPIN.NS O.01520983 O.03319887 O.11393334 O.21612337 O.22980248 http://www.streetinsider.com/PRNewswire/Lupin+Spins+Out+Two+Oncology+Programs+to+Kaveri+Therapeutics+to+Advance+its+Oncology+Strategy/26790919.html <div class="xn-content"> <p class="prntac">Aims to <span>Raise Capital</span> to Fund Global Clinical Studies for LNP7457 (PRMT5) &amp; LNP8701 (SOS1)</p><p><span class="legendSpanClass"><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location> and <location value="LU/us.fl.naples" idsrc="xmltag.org" >NAPLES, Fla.</location></span>, <span class="legendSpanClass"><chron>July 21, 2026</chron></span> /PRNewswire/ -- Global pharmaceutical leader <b><span value="Bombay:500257" idsrc="xmltag.org" >Lupin Limited</span> (Lupin) </b>(BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced the strategic spin-out of two oncology programs – <a target="_blank" href="https://www.lupin.com/media/press-releases/lupin-announces-presentation-of-phase-1-data-on-lnp7457-prmt5-inhibitor-at-the-american-society-of-clinical-oncology-annual-meeting-2025" target="_blank" rel="nofollow">LNP7457 (PRMT5)</a> and <a target="_blank" href="https://www.lupin.com/media/press-releases/lupin-shares-phase-1-data-on-lnp-8701-at-the-asco-annual-meeting-2026" target="_blank" rel="nofollow">LNP8701 (SOS1)</a>, through its wholly owned subsidiary, <span value="ACORN:1254228097" idsrc="xmltag.org" >Lupin Inc.</span>, into <b><span>Kaveri Therapeutics Inc.</span> (Kaveri)</b>, a <location value="LC/us" idsrc="xmltag.org" >U.S</location>.-based clinical-stage oncology company. Kaveri will advance these programs through http://www.streetinsider.com/PRNewswire/Lupin+Spins+Out+Two+Oncology+Programs+to+Kaveri+Therapeutics+to+Advance+its+Oncology+Strategy/26790919.html Tue, 21 Jul 2026 01:01:00 -0400 500257 500257 A.01721546 A.12542280 A.50208902 A.50216726 LUPIN.BO LUPIN.NS O.01520983 O.03319887 O.11393334 O.21612337 O.22980248 http://www.streetinsider.com/PRNewswire/Lupin+Spins+Out+Two+Oncology+Programs+to+Kaveri+Therapeutics+to+Advance+its+Oncology+Strategy/26790919.html <div class="xn-content"> <p class="prntac">Aims to <span>Raise Capital</span> to Fund Global Clinical Studies for LNP7457 (PRMT5) &amp; LNP8701 (SOS1)</p><p><span class="legendSpanClass"><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location> and <location value="LU/us.fl.naples" idsrc="xmltag.org" >NAPLES, Fla.</location></span>, <span class="legendSpanClass"><chron>July 21, 2026</chron></span> /PRNewswire/ -- Global pharmaceutical leader <b><span value="Bombay:500257" idsrc="xmltag.org" >Lupin Limited</span> (Lupin) </b>(BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced the strategic spin-out of two oncology programs – <a target="_blank" href="https://www.lupin.com/media/press-releases/lupin-announces-presentation-of-phase-1-data-on-lnp7457-prmt5-inhibitor-at-the-american-society-of-clinical-oncology-annual-meeting-2025" target="_blank" rel="nofollow">LNP7457 (PRMT5)</a> and <a target="_blank" href="https://www.lupin.com/media/press-releases/lupin-shares-phase-1-data-on-lnp-8701-at-the-asco-annual-meeting-2026" target="_blank" rel="nofollow">LNP8701 (SOS1)</a>, through its wholly owned subsidiary, <span value="ACORN:1254228097" idsrc="xmltag.org" >Lupin Inc.</span>, into <b><span>Kaveri Therapeutics Inc.</span> (Kaveri)</b>, a <location value="LC/us" idsrc="xmltag.org" >U.S</location>.-based clinical-stage oncology company. Kaveri will advance these programs through http://www.streetinsider.com/PRNewswire/Lupin+Spins+Out+Two+Oncology+Programs+to+Kaveri+Therapeutics+to+Advance+its+Oncology+Strategy/26790919.html Tue, 21 Jul 2026 01:01:00 -0400 500257 500257 A.01721546 A.12542280 A.50208902 A.50216726 LUPIN.BO LUPIN.NS O.01520983 O.03319887 O.11393334 O.21612337 O.22980248 http://www.streetinsider.com/PRNewswire/Lupin+Spins+Out+Two+Oncology+Programs+to+Kaveri+Therapeutics+to+Advance+its+Oncology+Strategy/26790919.html <div class="xn-content"> <p class="prntac">Aims to <span>Raise Capital</span> to Fund Global Clinical Studies for LNP7457 (PRMT5) &amp; LNP8701 (SOS1)</p><p><span class="legendSpanClass"><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location> and <location value="LU/us.fl.naples" idsrc="xmltag.org" >NAPLES, Fla.</location></span>, <span class="legendSpanClass"><chron>July 21, 2026</chron></span> /PRNewswire/ -- Global pharmaceutical leader <b><span value="Bombay:500257" idsrc="xmltag.org" >Lupin Limited</span> (Lupin) </b>(BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced the strategic spin-out of two oncology programs – <a target="_blank" href="https://www.lupin.com/media/press-releases/lupin-announces-presentation-of-phase-1-data-on-lnp7457-prmt5-inhibitor-at-the-american-society-of-clinical-oncology-annual-meeting-2025" target="_blank" rel="nofollow">LNP7457 (PRMT5)</a> and <a target="_blank" href="https://www.lupin.com/media/press-releases/lupin-shares-phase-1-data-on-lnp-8701-at-the-asco-annual-meeting-2026" target="_blank" rel="nofollow">LNP8701 (SOS1)</a>, through its wholly owned subsidiary, <span value="ACORN:1254228097" idsrc="xmltag.org" >Lupin Inc.</span>, into <b><span>Kaveri Therapeutics Inc.</span> (Kaveri)</b>, a <location value="LC/us" idsrc="xmltag.org" >U.S</location>.-based clinical-stage oncology company. Kaveri will advance these programs through http://www.streetinsider.com/PRNewswire/Lupin+Spins+Out+Two+Oncology+Programs+to+Kaveri+Therapeutics+to+Advance+its+Oncology+Strategy/26790919.html Tue, 21 Jul 2026 01:01:00 -0400 500257 500257 A.01721546 A.12542280 A.50208902 A.50216726 LUPIN.BO LUPIN.NS O.01520983 O.03319887 O.11393334 O.21612337 O.22980248 http://www.streetinsider.com/PRNewswire/Lupin+Spins+Out+Two+Oncology+Programs+to+Kaveri+Therapeutics+to+Advance+its+Oncology+Strategy/26790919.html <div class="xn-content"> <p class="prntac">Aims to <span>Raise Capital</span> to Fund Global Clinical Studies for LNP7457 (PRMT5) &amp; LNP8701 (SOS1)</p><p><span class="legendSpanClass"><location value="LU/in..bombay" idsrc="xmltag.org" >MUMBAI, India</location> and <location value="LU/us.fl.naples" idsrc="xmltag.org" >NAPLES, Fla.</location></span>, <span class="legendSpanClass"><chron>July 21, 2026</chron></span> /PRNewswire/ -- Global pharmaceutical leader <b><span value="Bombay:500257" idsrc="xmltag.org" >Lupin Limited</span> (Lupin) </b>(BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) today announced the strategic spin-out of two oncology programs – <a target="_blank" href="https://www.lupin.com/media/press-releases/lupin-announces-presentation-of-phase-1-data-on-lnp7457-prmt5-inhibitor-at-the-american-society-of-clinical-oncology-annual-meeting-2025" target="_blank" rel="nofollow">LNP7457 (PRMT5)</a> and <a target="_blank" href="https://www.lupin.com/media/press-releases/lupin-shares-phase-1-data-on-lnp-8701-at-the-asco-annual-meeting-2026" target="_blank" rel="nofollow">LNP8701 (SOS1)</a>, through its wholly owned subsidiary, <span value="ACORN:1254228097" idsrc="xmltag.org" >Lupin Inc.</span>, into <b><span>Kaveri Therapeutics Inc.</span> (Kaveri)</b>, a <location value="LC/us" idsrc="xmltag.org" >U.S</location>.-based clinical-stage oncology company. Kaveri will advance these programs through http://www.streetinsider.com/PRNewswire/Lupin+Spins+Out+Two+Oncology+Programs+to+Kaveri+Therapeutics+to+Advance+its+Oncology+Strategy/26790919.html Tue, 21 Jul 2026 01:01:00 -0400 500257 500257 A.01721546 A.12542280 A.50208902 A.50216726 LUPIN.BO LUPIN.NS O.01520983 O.03319887 O.11393334 O.21612337 O.22980248